GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » Land And Improvements

Asarina Pharma AB (OSTO:ASAP) Land And Improvements : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Asarina Pharma AB Land And Improvements?

Asarina Pharma AB's land and improvements for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Asarina Pharma AB Land And Improvements Historical Data

The historical data trend for Asarina Pharma AB's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Land And Improvements Chart

Asarina Pharma AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial - - - - -

Asarina Pharma AB Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Asarina Pharma AB Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Asarina Pharma AB Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB Headlines

No Headlines